Yes. Any solid tumor that is accesible for an injection and we have reason to suspect it would be sensitive to doxorubicin, would fit the criteria of this phase 1 study. For more info on the clinical trial please visit: https://clinicaltrials.gov/ct2/show/NCT04106492